Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
Laboratory of Hepatology, Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.
Transpl Int. 2024 Feb 19;37:12055. doi: 10.3389/ti.2024.12055. eCollection 2024.
malignancy (DNM) is the primary cause of mortality after liver transplantation (LT) for alcohol-related liver disease (ALD). However, data on risk factors for DNM development after LT are limited, specifically in patients with ALD. Therefore, we retrospectively analyzed all patients transplanted for ALD at our center before October 2016. Patients with a post-LT follow-up of <12 months, DNM within 12 months after LT, patients not on tacrolimus in the 1st year post-LT, and unknown smoking habits were excluded. Tacrolimus drug exposure level (TDEL) was calculated by area under the curve of trough levels in the 1st year post-LT. 174 patients received tacrolimus of which 19 (10.9%) patients developed a DNM between 12 and 60 months post-LT. Multivariate cox regression analysis identified TDEL [HR: 1.710 (1.211-2.414); = 0.002], age [1.158 (1.076-1.246); < 0.001], number of pack years pre-LT [HR: 1.021 (1.004-1.038); = 0.014] and active smoking at LT [HR: 3.056 (1.072-8.715); = 0.037] as independent risk factors for DNM. Tacrolimus dose minimization in the 1st year after LT and smoking cessation before LT might lower DNM risk in patients transplanted for ALD.
恶性肿瘤(DNM)是肝移植(LT)治疗酒精性肝病(ALD)后死亡的主要原因。然而,LT 后 DNM 发展的危险因素数据有限,特别是在ALD 患者中。因此,我们回顾性分析了 2016 年 10 月前在我们中心接受 LT 治疗的所有 ALD 患者。排除 LT 后随访时间<12 个月、LT 后 12 个月内发生 DNM、LT 后 1 年内未服用他克莫司且吸烟习惯未知的患者。通过 LT 后 1 年内的谷浓度曲线下面积计算他克莫司药物暴露水平(TDEL)。174 例患者接受他克莫司治疗,其中 19 例(10.9%)患者在 LT 后 12-60 个月内发生 DNM。多变量 Cox 回归分析确定 TDEL[HR:1.710(1.211-2.414);P=0.002]、年龄[1.158(1.076-1.246);P<0.001]、LT 前吸烟年数[HR:1.021(1.004-1.038);P=0.014]和 LT 时吸烟[HR:3.056(1.072-8.715);P=0.037]是 DNM 的独立危险因素。LT 后 1 年内减少他克莫司剂量和 LT 前戒烟可能会降低ALD 患者的 DNM 风险。